STANDARD BIOTOOLS INC.

LAB · XNAS

CIK 1162194fmd_1AR0WEB2AXHZ9F9WZX569HH7YQManufacturing · Pharmaceutical PreparationsTemplate: Standard

Coverage: Jan 01, 2009 to Sep 30, 2026, 67 periods

Income Statement · Annual · Millions · USD
Line item	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Total revenues	104	102	113	117	138	131	98	106	91	85
Cost of revenue	46	50	51	53	–	–	61	56	46	43
Gross profit	58	52	62	64	–	–	37	50	45	43
Research and development	38	31	30	32	36	38	37	26	29	26
Selling, general and administrative	93	80	80	84	98	99	102	88	103	110
Total operating expenses	132	110	161	169	189	198	153	127	172	153
Operating income	(73)	(58)	(48)	(52)	(51)	(67)	(116)	(77)	(127)	(110)
Interest expense	6	6	14	4	4	4	4	5	3	0
Other non-operating income (expense)	(1)	0	1	1	1	0	(1)	1	(5)	4
Income before taxes	(80)	(64)	(61)	(67)	(54)	(64)	(193)	(74)	(90)	(97)
Income tax expense	(4)	(3)	(2)	(2)	(1)	(4)	(3)	0	1	(38)
Net income from continuing operations	(76)	(61)	(59)	(65)	(53)	(59)	(190)	(75)	(91)	(59)
Net income	(76)	(61)	(59)	(65)	(53)	(59)	(190)	(75)	(139)	(75)
Net income to common shareholders	–	–	–	–	–	–	(190)	(75)	(185)	(75)